

Further Reading

1) What are the problems with existing statins?

Adherence rate

“Evidence suggests that between 40 and 75% of patients discontinue their statin therapy within one year after initiation. Furthermore, whilst the reasons for persistence with statin therapy are complex, evidence shows that low-adherence to statins negatively impacts clinical outcomes and residual CV risk remains a major concern.”

<https://www.sciencedirect.com/science/article/abs/pii/S0167527316324834>

2) What are the mechanisms thought to cause statin AE's?

“Atorvastatin Induces Mitochondria-Dependent Ferroptosis via the Modulation of Nrf2-xCT/GPx4 Axis”

<https://www.frontiersin.org/articles/10.3389/fcell.2022.806081/full>

“Effects of statins on mitochondrial pathways”

<https://pubmed.ncbi.nlm.nih.gov/33511728/#>

3) How do we expect Atorvo+™ combo will solve the problem?

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8385185/>

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7023045/>

4) What additional benefits might the Atorvo+™ combo have?

Is the cardiovascular system a therapeutic target for cannabidiol?

<https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/j.1365-2125.2012.04351.x>